15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Capricor Therapeutics Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $13.00 to $63.00 (about 4.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $49.67 sits 658% above the current $6.55. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.35 next quarter toward $-0.64 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Capricor Therapeutics Inc.
As of Jul, 6 of 6 firms rate CAPR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CAPR EPS & revenue forecast
EPS · NEXT QUARTER
$0.35
Range $-0.67 – $2.56 · 9 analysts · -164% YoY
Next period, 9 analysts expect Capricor Therapeutics Inc to earn $0.35 a share (range $-0.67 – $2.56), versus $-0.54 a year earlier. Full-year consensus is $-0.22, growing to $-0.64 the year after.
REVENUE · NEXT QUARTER
$53.5M
Range $0 – $200.0M · 9 analysts
Revenue is expected to reach $53.5M (range $0 – $200.0M). Full-year consensus is $118.1M, rising to $122.3M next year.
Top analysts covering Capricor Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CAPR.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$62.00+846.6% to target
Overall win rate
38%
+ Follow
#2
Leland Gershell
Oppenheimer · Rank #254
Buy
No targeton CAPR
Overall win rate
37%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$60.00+816.0% to target
Overall win rate
32%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #277
Buy
$58.00+785.5% to target
Overall win rate
29%
+ Follow
#5
Jason McCarthy
Maxim Group · Rank #360
Buy
$50.00+663.4% to target
Overall win rate
30%
+ Follow
CAPR stock forecast FAQ
What is CAPR's average 12-month price target?+
The 6 analysts with a live target average $49.67 for Capricor Therapeutics Inc over the next 12 months, ranging from a $63.00 high to a $13.00 low.
Is CAPR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CAPR?+
The Street-high target is $63.00 (B. Riley Securities), and the Street-low is $13.00 (Roth Capital). The average of all 6 active targets is $49.67.
How many Wall Street analysts cover CAPR?+
6 analysts have an active rating on Capricor Therapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering CAPR?+
Among analysts who currently cover CAPR, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #162). Their current call is Buy with a $62.00 target.
What is Capricor Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.35 per share (range $-0.67 – $2.56) across 9 analysts. Full-year EPS is projected at $-0.22, rising to $-0.64 the following year.
How much revenue is Capricor Therapeutics Inc expected to report next quarter?+
Consensus revenue is $53.5M (range $0 – $200.0M). Full-year revenue is projected at $118.1M, growing to $122.3M next year.
Have analysts been upgrading or downgrading CAPR lately?+
As of Jul, 6 of 6 firms rate CAPR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CAPR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
